The following pages link to Peter B. Gilbert (Q252811):
Displaying 50 items.
- Mark‐Specific Hazard Ratio Model with Multivariate Continuous Marks: An Application to Vaccine Efficacy (Q77966) (← links)
- Mark-specific hazard ratio model with missing multivariate marks (Q77969) (← links)
- Nonparametric bounds and sensitivity analysis of treatment effects (Q252812) (← links)
- Tests for comparing mark-specific hazards and cumulative incidence functions (Q702739) (← links)
- Proportional hazards models with continuous marks (Q1002166) (← links)
- Semiparametric efficient estimation in the generalized odds-rate class of regression models for right-censored time-to-event data (Q1277112) (← links)
- Goodness-of-fit tests for semiparametric biased sampling models (Q1416471) (← links)
- Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark (Q1660221) (← links)
- Analysis of generalized semiparametric regression models for cumulative incidence functions with missing covariates (Q1662316) (← links)
- Large sample theory of maximum likelihood estimates in semiparametric biased sampling models. (Q1848773) (← links)
- Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy (Q2001894) (← links)
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption (Q2170431) (← links)
- Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causes (Q2218811) (← links)
- New approaches for censored longitudinal data in joint modelling of longitudinal and survival data, with application to HIV vaccine studies (Q2274672) (← links)
- Nonparametric inference for immune response thresholds of risk in vaccine studies (Q2318678) (← links)
- Analysis of two-phase sampling data with semiparametric additive hazards models (Q2364040) (← links)
- Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling (Q2397797) (← links)
- Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model (Q2482986) (← links)
- (Q2769680) (← links)
- Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials (Q2846433) (← links)
- Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials (Q2861792) (← links)
- Quantile regression for competing risks data with missing cause of failure (Q2883906) (← links)
- Comparing Biomarkers as Principal Surrogate Endpoints (Q2893405) (← links)
- Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks (Q2911703) (← links)
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials (Q3076045) (← links)
- Omnibus Tests for Comparison of Competing Risks with Adjustment for Covariate Effects (Q3078825) (← links)
- Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations (Q3079023) (← links)
- Flexible Weighted Log-Rank Tests Optimal for Detecting Early and/or Late Survival Differences (Q3079059) (← links)
- Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials (Q3079146) (← links)
- Sensitivity Analyses Comparing Time-to-Event Outcomes Only Existing in a Subset Selected Postrandomization and Relaxing Monotonicity (Q3100820) (← links)
- (Q3295868) (← links)
- Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data (Q3303582) (← links)
- The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy (Q3526154) (← links)
- Testing and Estimation of Time‐Varying Cause‐Specific Hazard Ratios with Covariate Adjustment (Q3549395) (← links)
- Evaluating Candidate Principal Surrogate Endpoints (Q3549407) (← links)
- Weighted Likelihood Method for Grouped Survival Data in Case–Cohort Studies with Application to HIV Vaccine Trials (Q3549420) (← links)
- Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials (Q4238070) (← links)
- Hypothesis tests for stratified mark‐specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials (Q4563260) (← links)
- Smoothed Rank Regression for the Accelerated Failure Time Competing Risks Model with Missing Cause of Failure (Q4626675) (← links)
- Assessing Treatment‐Selection Markers using a Potential Outcomes Framework (Q4649041) (← links)
- Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types (Q4666022) (← links)
- Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials (Q4916438) (← links)
- A Multiple Imputation Approach for the Evaluation of Surrogate Markers in the Principal Stratification Causal Inference Framework (Q4984852) (← links)
- Causal Isotonic Regression (Q5087153) (← links)
- Semiparametric Estimation of Treatment Effects Given Base-Line Covariates on an Outcome Measured After a Post-Randomization Event Occurs (Q5088202) (← links)
- Analysis of generalized semiparametric mixed varying‐coefficients models for longitudinal data (Q5107591) (← links)
- General regression model for the subdistribution of a competing risk under left-truncation and right-censoring (Q5145708) (← links)
- Generalized semiparametric varying‐coefficient model for longitudinal data with applications to adaptive treatment randomizations (Q5283300) (← links)
- Model‐robust inference for continuous threshold regression models (Q5283301) (← links)
- Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization (Q5307658) (← links)
